Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Completed 1

Sponsor Class

OTHER 32UNKNOWN 2NIH 1INDUSTRY 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Extrapancreatic Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

Capecitabine 15Paclitaxel 13S 1 (combination) 9apatinib 8Oxaliplatin 8Carboplatin 8Cisplatin 7pyrotinib 6Epirubicin 6Docetaxel 6sintilimab 5camrelizumab 5anlotinib 5Radiotherapy 5Drug Therapy 5130-nm albumin-bound paclitaxel 5nimotuzumab 4nedaplatin 4Vinorelbine 4Temozolomide 4Irinotecan 4Fulvestrant 4Etoposide 4Bevacizumab 4toripalimab 3titanium silicide 3exemestane 3Trastuzumab 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × UNKNOWN × Tegafur × Clear all
NCT03204019 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled

Adenoma, Islet Cell

NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡